서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 18 of 18

Issue DateTitle / Author(s) / CitationFileAltmetrics
2010-09
A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma
DOI
2011-02
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
DOI
2011-12
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
DOI
2014-11
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial
DOI
2015-07
Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review

Park, Joon Oh; Oh, Do-Youn; Hsu, Chiun; Chen, Jen-Shi; Chen, Li-Tzong; Orlando, Mauro; Kim, Jong Seok; Lim, Ho Yeong

Cancer Research and Treatment, Vol.47 No.3, pp.343-361

DOI
2017-12
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
DOI
2020-01
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
DOI
2020-02
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study
DOI
2020-05
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
DOI
2021-04
Efficacy of pembrolizumab monotherapy for advanced gastric/gastroesophageal junction cancer with programmed death ligand 1 combined positive score ≥10
DOI
2021-07
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
DOI
2021-10
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study
DOI
2022-01
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
DOI
2022-02
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
DOI
2023-11
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer
DOI
2024-08
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
DOI
2024-08
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

Oh, Do-Youn; He, Aiwu Ruth; Bouattour, Mohamed; Okusaka, Takuji; Qin, Shukui; Chen, Li-Tzong; Kitano, Masayuki; Lee, Choong-kun; Kim, Jin Won; Chen, Ming-Huang; Suksombooncharoen, Thatthan; Ikeda, Masafumi; Lee, Myung Ah; Chen, Jen-Shi; Potemski, Piotr; Burris, Howard A; Ostwal, Vikas; Tanasanvimon, Suebpong; Morizane, Chigusa; Zaucha, Renata E; McNamara, Mairéad G; Avallone, Antonio; Cundom, Juan E; Breder, Valeriy; Tan, Benjamin; Shimizu, Satoshi; Tougeron, David; Evesque, Ludovic; Petrova, Mila; Zhen, David B; Gillmore, Roopinder; Gupta, Vineet Govinda; Dayyani, Farshid; Park, Joon Oh; Buchschacher, Gary L; Rey, Felipe; Kim, Hyosung; Wang, Julie; Morgan, Claire; Rokutanda, Nana; Żotkiewicz, Magdalena; Vogel, Arndt; Valle, Juan W

The Lancet Gastroenterology & Hepatology, Vol.9 No.8, pp.694-704

DOI
2024-11
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
DOI
1